全部商品分类









PBS, 40% Glycerol, 0.05% BSA, 0.03% Proclin 300




ELISA
Sandwich ELISA
CLIA
Lateral Flow
Dot Blot
WB
1:1000IP
IHC-P
1:500ICC
IF
ICFCM
FCM
mIHC
ChIP

CCL21 (also known as secondary lymphoid tissue chemokine SLC or Exodus-2) is a CC-type chemokine of approximately 12.2 kDa consisting of 111 amino acids, encoded by the CCL21 gene on chromosome 9p13.3. Its structure is highly distinctive: although it contains a conserved chemokine domain (including the N-loop and third β-strand) and exists as a monomer, it differs from most family members by possessing six cysteines (two more than typical CC chemokines) and an exceptionally long, unstructured carboxyl-terminal tail. This C-terminal region, while not involved in canonical chemokine folding, facilitates CCL21 anchoring to the surface of lymphatic endothelial cells via glycosaminoglycan binding. Under physiological conditions, CCL21 is predominantly expressed by endothelial cells of secondary lymphoid organs such as lymph nodes, spleen, and appendix. It binds via tyrosine 12 (Y12) in its N-loop and the third β-strand to the N-terminus of the G protein-coupled receptor CCR7 with a dissociation constant of approximately 150 μM, activating downstream signaling pathways including JAK/STAT. This interaction exerts potent chemotactic effects on CCR7⁺ cells (e.g., naïve T cells and dendritic cells), driving their homing to lymphoid organs and establishing immune microenvironments. In the oncological context, however, the CCL21/CCR7 axis exhibits a pronounced double-edged sword effect: various solid tumors—including melanoma and breast cancer—hijack this homing mechanism to actively metastasize to the lymphatic system. Moreover, aberrant CCL21 expression within the primary tumor microenvironment recruits immunosuppressive cells and constructs pro-tumor lymphoid niches, directly correlating with poor prognosis in patients.


12 months from date of receipt / reconstitution, -20 °C as supplied






用小程序,查商品更便捷


